ArticleHuman vaccines & immunotherapeutics2013
Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.Virologica Sinica · 2015Pooled it
- Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.The Journal of infectious diseases · 2022Trial
- Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation.Vaccines · 2026Review
- Knowledge, attitudes, and practices of pediatricians in Crete, Greece, regarding RSV immunization: a cross-sectional study.European journal of pediatrics · 2026Article
- From setbacks to success: lessons from the journey of RSV vaccine development.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Incidence and risk factors of hospitalisations for respiratory syncytial virus among children aged less than 2 years.Epidemiology and infection · 2022Article
- Is the Host Viral Response and the Immunogenicity of Vaccines Altered in Pregnancy?Antibodies (Basel, Switzerland) · 2020Article
- Comparisons between ethnic groups in hospitalizations for respiratory syncytial virus bronchiolitis in Israel.PloS one · 2019Article
- A multifaceted approach to RSV vaccination.Human vaccines & immunotherapeutics · 2018Review
- Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma.Frontiers in immunology · 2018Review
- Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.The Journal of infectious diseases · 2017Article
- New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.International journal of molecular sciences · 2017Review
- Preclinical assessment of safety of maternal vaccination against respiratory syncytial virus (RSV) in cotton rats.Vaccine · 2017Article
- Improving rates of maternal immunization: Challenges and opportunities.Human vaccines & immunotherapeutics · 2016Article
- Article
- Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Infectious diseases and therapy · 2014Review
- Article
- Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.Immunology · 2014Review
- Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Frontiers in immunology · 2014Review
- Parents' attitude toward multiple vaccinations at a single visit with alternative delivery methods.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness (LRI) in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder, and the elderly are at increased risk for severe LRI upon RSV infection. Although there is at present no licensed RSV vaccine available, it is a priority target for several vaccine developers. For the implementation of a future RSV vaccination within national immunization schemes, various strategies can be considered even without the availability of extended clinical data on RSV vaccines. For this purpose, the extensive knowledge on RSV with respect to disease pathology, epidemiology and immunology can be used. This article discusses different aspects that should be considered to enable a successful implementation of a new RSV vaccine in national immunization programs. In addition, gaps in knowledge that needs further attention are identified. The maternal immunization strategy is highlighted, but also vaccination in the youngest infants and specific risk group immunization strategies are evaluated in this paper. Key factors such as the seasonality of RSV disease, interference of maternal antibodies and the immaturity of the infants' immune system are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.